CRISPR Therapeutics (CRSP) Tops Q3 EPS by 58c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mail
Get Alerts CRSP Hot Sheet
Join SI Premium – FREE
CRISPR Therapeutics (NASDAQ: CRSP) reported Q3 EPS of ($1.41), $0.58 better than the analyst estimate of ($1.99).
For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UnitedHealth Group (UNH) Tops Q3 EPS by 57c, Beats on Revenue; Offers FY EPS Guidance
- BofA Securities Starts Riyadh Cables (4142:SE) at Buy
- Mizuho Upgrades Rexford Industrial Realty (REXR) to Outperform
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
